Eric Hoffman (ReveraGen Biopharma) presents the Phase 2a results at the PPMD conference 2018. Click on the presentation to view.
Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-
class dissociative steroidal anti-inflammatory drug
–Read the publication here
